| Main Subject |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Networking > The De-Attraction Principle |
|
Main Subject - The De-Attraction Principle
Recently I have attended several networking events where I was amazed to find out that there were several people from According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product the same business attending the event too. What was amazing was that those people sat right next to each other at t ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in he same tables. What were they thinking? In the one instance those people were at the table where I chose to sit. lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. tried to strike up a conversation with the person to my right, and no matter what I asked I was met with conversatio here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe n ending answers. It sure did make me hesitant about speaking to the two additional people representing the same com d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro any. The person who didn’t feel like conversing essentially acted as a barrier to the other two people sitting to he ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc r right. Now I guess I’m going to have to get more creative with my questions in the future. Maybe at my next event easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi I will ask if they can share their favorite story about a success. So I must take some responsibility. Perhaps that nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically day I wasn’t on my best with the questions I asked! But let’s face it. Have I been left with a good impression of and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ he company these people represent? I can tell you that it would take a considerable amount of effort on that company ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi ’s part to get me to think favorable of them in the future. The solution is so simple that I hate to even mention it ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a . But sometimes the obvious is clouded by all the small details. If you are attending a networking event with a col dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod eague, PLEASE part company at the door. You will be doing a huge favor for yourself, your colleague and your company cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin . Groups of people deliver silent body language that they are a closed entity. It is very difficult for someone to tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen pproach when those signals are being transmitted. Additionally, if someone is trying to show interest in you, play t t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel he game. Give some creative answers. Ask some equally fascinating questions in return. Networking is an active spo ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust t, not for those who want to stay on the sidelines. If you find your colleagues more interesting than prospective cu y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products stomers or referral sources, then stay away from networking events. Go to lunch with just your colleagues. Those bi . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de networking breakfasts, lunches or business after hours can be daunting. If you smile, make eye contact and generall elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip y act like an interesting person, the pay-off will be more customers, more friends and a fuller more interesting life tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Cost Estimating Is The First Thing After Plans If You Are Planning On Building A Structure All You Wanted To Know About B2B Portals Getting the Most from Your Graphic Designer
|